Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients-Reference-Cited by-同舟云学术

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Published:2018-01 Issue: Volume:29 Page:i20-i27
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Remon J.,Steuer C.E.,Ramalingam S.S.,Felip E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/suppl_1/i20/23947309/mdx704.pdf

Reference78 articles.

1. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors;Reguart;Future Oncol,2015

2. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study;Shi;Ann Oncol,2017

3. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

4. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP;Yun;Proc Natl Acad Sci U S A,2008

5. Analysis of tumour specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin Cancer Res,2013

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trefoil factor 1 (TFF1) reduces cerebral edema and gastric mucosal injury by regulating the EGFR/Src/FAK pathway in an intracerebral hemorrhage rat model;Neuropeptides;2024-10

2. Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19;Frontiers in Immunology;2024-09-06

3. Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?;Cancers;2024-08-28

4. Current clinical practice and physicians’ insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation;BMC Cancer;2024-08-23

5. Downregulation of Rad51 Expression and Activity Potentiates the Cytotoxic Effect of Osimertinib in Human Non-Small Cell Lung Cancer Cells;Chemotherapy;2024-08-10